<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:56.4pt;left:116.6pt;line-height:9.4pt"><span style="font-family:Times New Roman,serif;font-size:9.4pt;color:#000101">International Journal of</span><span style="font-family:Times New Roman,serif;font-size:8.8pt;color:#612d64"> </span><sup><b><i><span style="font-family:Times New Roman,serif;font-size:8.8pt;color:#4f4424"> </span></i></b></sup></p>
<p style="top:67.9pt;left:116.6pt;line-height:11.3pt"><b><i><span style="font-family:Times New Roman,serif;font-size:11.3pt;color:#3a1b3c">Molecular Sciences</span></i></b></p>
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<p style="top:100.5pt;left:76.2pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Review</span></i></p>
<p style="top:113.4pt;left:76.5pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Chondroprotective Actions of Selective COX-2</span></b></p>
<p style="top:133.6pt;left:76.5pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Inhibitors In Vivo: A Systematic Review</span></b></p>
<p style="top:168.5pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Ufuk Tan Timur</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">*, Marjolein M. J. Caron</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Ralph M. Jeuken</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Yvonne M. Bastiaansen-Jenniskens</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">2</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span></b></p>
<p style="top:182.0pt;left:76.2pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Tim J. M. Welting</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Lodewijk W. van Rhijn</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Gerjo J. V. M. van Osch</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">2,3</span></b></sup><sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> </span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and Pieter J. Emans</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup></p>
<p style="top:199.2pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">1</span></p>
<p style="top:200.9pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Laboratory for Experimental Orthopedics, Department of Orthopaedic Surgery, Maastricht University</span></p>
<p style="top:213.0pt;left:97.4pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Medical Centre</span><span style="font-family:Rpxr,serif;font-size:8.9pt">+</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 6229 HX Maastricht, The Netherlands; marjolein.caron@maastrichtuniversity.nl (M.M.J.C.);</span></p>
<p style="top:225.1pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">r.jeuken@maastrichtuniversity.nl (R.M.J.); t.welting@maastrichtuniversity.nl (T.J.M.W.);</span></p>
<p style="top:237.2pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">l.van.rhijn@mumc.nl (L.W.v.R.); p.emans@mumc.nl (P.J.E.)</span></p>
<p style="top:247.6pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">2</span></p>
<p style="top:249.3pt;left:97.4pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Department of Orthopaedics, Erasmus MC University Medical Center, Wytemaweg 80, 3015 CN Rotterdam,</span></p>
<p style="top:261.4pt;left:97.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">The Netherlands; y.bastiaansen@erasmusmc.nl (Y.M.B.-J.); g.vanosch@erasmusmc.nl (G.J.V.M.v.O.)</span></p>
<p style="top:271.8pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">3</span></p>
<p style="top:273.5pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Department of Otorhinolaryngology, Erasmus MC University Medical Center, Wytemaweg 80,</span></p>
<p style="top:285.6pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3015 CN Rotterdam, The Netherlands</span></p>
<p style="top:297.7pt;left:81.4pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">*</span></b></p>
<p style="top:297.7pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Correspondence: u.timur@maastrichtuniversity.nl</span></p>
<p style="top:323.7pt;left:82.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Received: 29 August 2020; Accepted: 18 September 2020; Published: 22 September 2020</span></p>
<p style="top:315.7pt;left:487.1pt;line-height:7.9pt"><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span><span style="font-family:SourceSansRoman.613wght,serif;font-size:7.0pt">&#xfffd;</span></p>
<p style="top:322.8pt;left:487.1pt;line-height:7.9pt"><b><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span></b></p>
<p style="top:347.0pt;left:81.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Abstract:</span></b><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Knee osteoarthritis (OA) is a condition mainly characterized by cartilage degradation.</span></p>
<p style="top:360.6pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Currently, no e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ective treatment exists to slow down the progression of OA-related cartilage damage.</span></p>
<p style="top:374.0pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Selective COX-2 inhibitors may, next to their pain killing properties, act chondroprotective</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">.</span></p>
<p style="top:387.6pt;left:81.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">To determine whether the route of administration is important for the e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cacy of the chondroprotective</span></p>
<p style="top:401.2pt;left:81.9pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">properties of selective COX-2 inhibitors, a systematic review was performed according to the PRISMA</span></p>
<p style="top:414.6pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">guidelines. Studies investigating OA-related cartilage damage of selective COX-2 inhibitors</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span></p>
<p style="top:428.0pt;left:81.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">were included. Nine of the fourteen preclinical studies demonstrated chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects of</span></p>
<p style="top:441.5pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">selective COX-2 inhibitors using systemic administration. Five clinical studies were included and,</span></p>
<p style="top:455.2pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">although in general non-randomized, failed to demonstrate chondroprotective actions of oral selective</span></p>
<p style="top:468.7pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">COX-2 inhibitors. All of the four preclinical studies using bolus intra-articular injections demonstrated</span></p>
<p style="top:482.1pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">chondroprotective actions, while one of the three preclinical studies using a slow release system</span></p>
<p style="top:495.6pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">demonstrated chondroprotective actions. Despite the limited evidence in clinical studies that have</span></p>
<p style="top:509.2pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">used the oral administration route, there seems to be a preclinical basis for considering selective COX-2</span></p>
<p style="top:522.6pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibitors as disease modifying osteoarthritis drugs when used intra-articularly. Intra-articularly</span></p>
<p style="top:536.3pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">injected selective COX-2 inhibitors may hold the potential to provide chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span></p>
<p style="top:549.7pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in clinical studies.</span></p>
<p style="top:575.1pt;left:82.2pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Keywords:</span></b><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> selective COX-2 inhibitors; intra-articular injection; knee osteoarthritis; DMOADs</span></p>
<p style="top:626.1pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">1. Introduction</span></b></p>
<p style="top:645.6pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Knee osteoarthritis (OA) is a condition that leads to pain and is mainly characterized by cartilage</span></p>
<p style="top:659.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">degradation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">1</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Currently, drug treatments provide symptomatic pain relief but no e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ective treatment</span></p>
<p style="top:672.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">exists to slow down progression of OA-related cartilage damage [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">1</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Pain-killing drug therapies</span></p>
<p style="top:686.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">include non-steroidal anti-in&#xfb02;ammatory drugs (NSAIDs). NSAIDs provide pain relief by blocking</span></p>
<p style="top:699.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cyclooxygenase (COX)-dependent prostanoid synthesis. Prostanoids are an important family of</span></p>
<p style="top:713.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">signaling molecules present in synovial &#xfb02;uid [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. At least two COX isoforms have been described,</span></p>
<p style="top:726.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">COX-1 and COX-2, the latter being considered as the in&#xfb02;ammatory isoform [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Selective COX-2</span></p>
<p style="top:740.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">inhibitors have been developed to speci&#xfb01;cally target the in&#xfb02;ammatory COX-2 while circumventing</span></p>
<p style="top:753.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibition of the COX-1 isoform. While selective COX-2 inhibitors may provide an e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ective means for</span></p>
<p style="top:793.0pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962; doi:10.3390</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ijms21186962</span></p>
<p style="top:793.0pt;left:417.3pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">www.mdpi.com</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">journal</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ijms</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2 of 15</span></p>
<p style="top:89.8pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">pain relief, targeting the in&#xfb02;ammatory COX-2 may be also a promising approach to inhibit cartilage</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">degradation and thereby slow down knee OA progression [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. This hypothesis is supported by the</span></p>
<p style="top:116.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">accumulating evidence showing that in&#xfb02;ammation precedes OA disease progression [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:130.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">From the anti-nerve growth factor clinical trials it became clear that next to a substantial</span></p>
<p style="top:143.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">improvement in pain, patients also displayed structural OA disease progression [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. This emphasizes</span></p>
<p style="top:157.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the importance of treatment strategies not only providing pain relief, which will lead to a vicious</span></p>
<p style="top:170.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">self-perpetuating cycle of joint overloading and OA progression, but also providing the ability for</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">disease modi&#xfb01;cation.</span></p>
<p style="top:197.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The actions of non-selective COX inhibitors on cartilage degradation</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> and</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> have</span></p>
<p style="top:211.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">been excellently reviewed in the past [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">6</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Moreover, ex vivo and</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> actions of the selective COX-2</span></p>
<p style="top:224.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">inhibitor celecoxib on cartilage degradation, synovial in&#xfb02;ammation and osteoclast metabolism have</span></p>
<p style="top:238.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">also been reviewed and date back to 2011 [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">7</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Recently, an updated review of studies published until</span></p>
<p style="top:251.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">2016 has been conducted on the OA disease-modifying actions of celecoxib on di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent OA tissues.</span></p>
<p style="top:265.4pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">This review con&#xfb01;rms the contradictive reports regarding the chondroprotective actions of celecoxib</span></p>
<p style="top:278.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">both ex vivo and</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">. Based on these reviews, it still remains obscure whether selective COX-2</span></p>
<p style="top:292.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibitors can be used</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt"> to protect cartilage and slow down the progression of knee OA. One of</span></p>
<p style="top:306.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the explanations of the contradictive reports found in the literature regarding the potential of selective</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">COX-2 inhibitors may be related to the route of administration. Speci&#xfb01;cally, scarcely vascularized</span></p>
<p style="top:333.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">tissues such as cartilage and meniscus, which are important participants in knee OA, may be modi&#xfb01;ed</span></p>
<p style="top:346.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erentially after systemic oral treatment compared to intra-articular treatment [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">9</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. To date, the role</span></p>
<p style="top:360.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of the route of administration on the chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of selective COX-2 inhibitors remains</span></p>
<p style="top:373.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">unclear. Therefore, the objective of this review was to systematically review available literature on</span></p>
<p style="top:387.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">chondroprotective properties of selective COX-2 inhibitors in preclinical models for OA or in clinical</span></p>
<p style="top:400.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">OA studies depending on the route of administration.</span></p>
<p style="top:423.8pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2. Results</span></b></p>
<p style="top:443.2pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The search strategy yielded 25 articles for inclusion (Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">). We identi&#xfb01;ed preclinical and</span></p>
<p style="top:456.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical studies investigating chondroprotective actions of selective COX-2 inhibitors either via systemic</span></p>
<p style="top:470.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">administration or via intra-articular delivery. Using the SYRCLE&#x2019;s risk of bias tool for preclinical studies,</span></p>
<p style="top:483.9pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">we observed that outcome measurements were in general blinded, but randomization sequences were</span></p>
<p style="top:497.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">not always reported increasing the risk for selection bias (supplementary data) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">10</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. For clinical studies,</span></p>
<p style="top:510.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the Cochrane risk bias tool revealed that clinical studies were non-randomized, displaying a high risk</span></p>
<p style="top:524.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of selection and performance bias (supplementary data) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">11</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:537.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The following sections will discuss the main results of the included 25 studies and compare</span></p>
<p style="top:551.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">chondroprotective actions of selective COX-2 inhibitors when used systemically or intra-articularly.</span></p>
<p style="top:574.6pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.1. Preclinical Studies: Oral and Intraperitoneal Administration</span></i></p>
<p style="top:594.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Fourteen of the included studies have investigated chondroprotective actions of selective COX-2</span></p>
<p style="top:607.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibitors after systemic administration (Table</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">). Most studies focused on chondroprotective actions</span></p>
<p style="top:621.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">of the selective COX-2 inhibitor celecoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], while other studies investigated chondroprotective</span></p>
<p style="top:634.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">actions of meloxicam [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] and etoricoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Four studies that investigated chondroprotective</span></p>
<p style="top:648.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">actions of selective COX-2 inhibitors in surgically induced OA models failed to demonstrate</span></p>
<p style="top:661.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">chondroprotective actions when the drug was administered directly after OA induction [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:675.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">On the other hand, Dai et al. demonstrated chondroprotective actions of celecoxib, as evidenced by an</span></p>
<p style="top:688.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">improved macroscopic and histological OARSI score, in a surgically induced pig OA model, in which</span></p>
<p style="top:702.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">treatment was started one week after surgery [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Further support of chondroprotective actions of</span></p>
<p style="top:715.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">selective COX-2 inhibitors comes from a study in a surgically induced rat OA model, where treatment</span></p>
<p style="top:729.1pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with oral etoricoxib decreased OA-related cartilage damage as evidenced by an improved Pritzker</span></p>
<p style="top:742.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">score compared to controls [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Chondroprotective actions of celecoxib were also shown in a study in</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 of 15</span></p>
<p style="top:89.9pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">which the Achilles tendon transection rat knee OA model was used [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It was shown that compared</span></p>
<p style="top:103.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to controls, chondrocyte apoptosis was lower after oral administration of celecoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:67.0pt;left:92.3pt;line-height:8.0pt"><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:8.0pt">Int. J. Mol. Sci. </span></i><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:8.0pt">2020</span></b><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, </span><i><span style="font-family:PalatinoLinotype,Italic,serif;font-size:8.0pt">21</span></i><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">, x FOR PEER REVIEW </span></p>
<p style="top:67.0pt;left:487.4pt;line-height:8.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:8.0pt">3 of 15 </span></p>
<p style="top:804.3pt;left:92.3pt;line-height:9.0pt"><span style="font-family:Times New Roman,serif;font-size:9.0pt"> </span></p>
<p style="top:90.3pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">was used [15]. It was shown that </span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt;color:#1c1717">compared to controls, chondrocyte apoptosis was lower after oral </span></p>
<p style="top:103.8pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt;color:#1c1717">administration of celecoxib [15].</span><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt"> </span></p>
<p style="top:458.8pt;left:479.2pt;line-height:12.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:12.0pt"> </span></p>
<p style="top:478.2pt;left:92.5pt;line-height:9.0pt"><b><span style="font-family:PalatinoLinotype,Bold,serif;font-size:9.0pt">Figure 1. </span></b><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">PRISMA flowchart showing the yield of the search and inclusion of studies leading to the </span></p>
<p style="top:491.2pt;left:92.5pt;line-height:9.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:9.0pt">25 included studies. </span></p>
<p style="top:515.6pt;left:92.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">Next to surgically induced OA models, the monosodium iodoacetate (MIA) rat OA model </span></p>
<p style="top:529.1pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">[16,17,23], the collagenase OA model [13,19] and the spontaneous OA mouse model (STR/Ort) [21] </span></p>
<p style="top:542.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">were also used to investigate chondroprotective actions of selective COX-2 inhibitors celecoxib </span></p>
<p style="top:556.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">[13,16,17,19,21] and meloxicam [23]. In these studies, chondroprotective actions of selective COX-2 </span></p>
<p style="top:569.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">inhibitors were observed after oral administration as evidenced by improved histological scores </span></p>
<p style="top:583.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">compared to the controls. </span></p>
<p style="top:596.5pt;left:92.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">While the aforementioned studies investigated chondroprotective actions of drugs administered </span></p>
<p style="top:610.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">orally, one study investigated chondroprotective actions of etoricoxib when administered </span></p>
<p style="top:623.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">intraperitoneally [25]. In this study, treatment with intraperitoneal etoricoxib injections was started </span></p>
<p style="top:637.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">two days after surgically inducing OA using the destabilization of the medial meniscus (DMM) </span></p>
<p style="top:650.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">mouse model [25] and histological analysis did not demonstrate a reduction in OA-related cartilage </span></p>
<p style="top:664.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">damage. </span></p>
<p style="top:677.5pt;left:92.5pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">In conclusion, there is conflicting evidence regarding the chondroprotective actions of </span></p>
<p style="top:691.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">systemically administered selective COX-2 inhibitors since five studies did not show </span></p>
<p style="top:704.5pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">chondroprotective actions, while nine studies showed chondroprotective actions after systemic </span></p>
<p style="top:718.0pt;left:71.3pt;line-height:10.0pt"><span style="font-family:PalatinoLinotype,serif;font-size:10.0pt">administration with selective COX-2 inhibitors.</span></p>
<img style="position:absolute;transform:matrix(.59865388,0,-0,.598,-26.169342,17.301362)" src="data:image/png;base64,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">
<p style="top:472.1pt;left:97.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> PRISMA &#xfb02;owchart showing the yield of the search and inclusion of studies leading to the 25</span></p>
<p style="top:484.9pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">included studies.</span></p>
<p style="top:507.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Next to surgically induced OA models, the monosodium iodoacetate (MIA) rat OA model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">],</span></p>
<p style="top:521.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the collagenase OA model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">13</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] and the spontaneous OA mouse model (STR</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Ort) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] were also used</span></p>
<p style="top:534.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to investigate chondroprotective actions of selective COX-2 inhibitors celecoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">13</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] and</span></p>
<p style="top:548.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">meloxicam [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In these studies, chondroprotective actions of selective COX-2 inhibitors were observed</span></p>
<p style="top:561.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">after oral administration as evidenced by improved histological scores compared to the controls.</span></p>
<p style="top:588.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">orally,</span><sup><span style="font-family:URWPalladioL,serif;font-size:9.9pt">While the aforementioned studies investigated chondroprotective actions of drugs administered</span></sup></p>
<p style="top:588.4pt;left:112.4pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">one study investigated chondroprotective actions of etoricoxib when administered</span></p>
<p style="top:602.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">intraperitoneally [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. In this study, treatment with intraperitoneal etoricoxib injections was started</span></p>
<p style="top:615.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">two days after surgically inducing OA using the destabilization of the medial meniscus (DMM) mouse</span></p>
<p style="top:629.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] and histological analysis did not demonstrate a reduction in OA-related cartilage damage.</span></p>
<p style="top:642.6pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In conclusion, there is con&#xfb02;icting evidence regarding the chondroprotective actions of systemically</span></p>
<p style="top:656.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">administered selective COX-2 inhibitors since &#xfb01;ve studies did not show chondroprotective actions,</span></p>
<p style="top:669.5pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">while nine studies showed chondroprotective actions after systemic administration with selective</span></p>
<p style="top:683.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">COX-2 inhibitors.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:742.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4 of 15</span></p>
<p style="top:89.7pt;left:164.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The schematic of studies investigating chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ects of systemically administered selective COX-2 inhibitors.</span></p>
<p style="top:110.0pt;left:345.3pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Preclinical Studies Using Oral Administration</span></b></p>
<p style="top:127.1pt;left:108.0pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Authors</span></b></p>
<p style="top:127.1pt;left:167.3pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Species</span></b></p>
<p style="top:127.1pt;left:205.5pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">COX-2 Inhibitor</span></b></p>
<p style="top:127.1pt;left:278.9pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA Model</span></b></p>
<p style="top:127.1pt;left:332.2pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Dosing Regime</span></b></p>
<p style="top:127.1pt;left:398.0pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Start of Treatment</span></b></p>
<p style="top:122.8pt;left:487.4pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Timepoint of</span></b></p>
<p style="top:131.5pt;left:491.1pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Evaluation</span></b></p>
<p style="top:122.8pt;left:566.8pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Evaluation of Cartilage</span></b></p>
<p style="top:131.5pt;left:584.1pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Degradation</span></b></p>
<p style="top:127.1pt;left:684.9pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Main Findings</span></b></p>
<p style="top:152.9pt;left:86.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Mastbergen et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:152.9pt;left:168.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Canine</span></p>
<p style="top:152.9pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:152.9pt;left:284.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Groove</span></p>
<p style="top:152.9pt;left:336.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 200 mg</span></p>
<p style="top:152.9pt;left:393.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after surgery</span></p>
<p style="top:148.5pt;left:486.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">15 weeks after</span></p>
<p style="top:157.3pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:144.1pt;left:560.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology:Modi&#xfb01;ed Mankin</span></p>
<p style="top:152.9pt;left:563.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Biochemistry: PG content,</span></p>
<p style="top:161.7pt;left:571.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">synthesis and release</span></p>
<p style="top:144.1pt;left:664.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in histological</span></p>
<p style="top:152.9pt;left:667.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">scores, no di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in PG</span></p>
<p style="top:161.7pt;left:664.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">content, synthesis or release</span></p>
<p style="top:191.8pt;left:98.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Huh et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">13</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:191.8pt;left:169.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rabbit</span></p>
<p style="top:191.8pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:191.8pt;left:277.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Collagenase</span></p>
<p style="top:191.8pt;left:331.8pt;line-height:7.1pt"><span style="font-family:URWPalladioL,serif;font-size:7.1pt">Daily 100 mg</span><span style="font-family:Rpxr,serif;font-size:7.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.1pt">kg</span></p>
<p style="top:187.4pt;left:406.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after</span></p>
<p style="top:196.2pt;left:405.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:187.4pt;left:488.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">4 weeks after</span></p>
<p style="top:196.2pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:174.3pt;left:557.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: Colombo score for</span></p>
<p style="top:183.0pt;left:559.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">cartilage and synovitis score</span></p>
<p style="top:191.8pt;left:558.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">for synoviummRNA analysis</span></p>
<p style="top:200.6pt;left:568.7pt;line-height:7.2pt"><i><span style="font-family:URWPalladioL,serif;font-size:7.2pt">PTGS1, PTGS2</span></i><span style="font-family:URWPalladioL,serif;font-size:7.2pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> MMP1</span></i></p>
<p style="top:209.3pt;left:586.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">and</span><i><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> MMP3</span></i></p>
<p style="top:174.3pt;left:665.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved histological score</span></p>
<p style="top:183.0pt;left:675.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">in celecoxib group vs.</span></p>
<p style="top:191.8pt;left:667.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">control, decreased MMP-1</span></p>
<p style="top:200.6pt;left:675.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">mRNA expression in</span></p>
<p style="top:209.3pt;left:666.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">celecoxib group vs. control</span></p>
<p style="top:226.3pt;left:97.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Jones et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">22</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:226.3pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:226.3pt;left:214.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Meloxicam</span></p>
<p style="top:221.9pt;left:272.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">MCLT</span><span style="font-family:Rpxr,serif;font-size:7.2pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> ACLT</span></p>
<p style="top:230.7pt;left:283.8pt;line-height:7.2pt"><span style="font-family:Rpxr,serif;font-size:7.2pt">+</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> MMx</span></p>
<p style="top:226.3pt;left:335.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 3 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:221.9pt;left:406.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after</span></p>
<p style="top:230.7pt;left:405.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:221.9pt;left:488.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">8 weeks after</span></p>
<p style="top:230.7pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:226.3pt;left:560.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology:Modi&#xfb01;ed Mankin</span></p>
<p style="top:221.9pt;left:664.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in histological</span></p>
<p style="top:230.7pt;left:664.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">score meloxicam vs. control</span></p>
<p style="top:247.7pt;left:96.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Fukai et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:247.7pt;left:168.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Mouse</span></p>
<p style="top:247.7pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:247.7pt;left:273.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">MCLT</span><span style="font-family:Rpxr,serif;font-size:7.2pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> MMx</span></p>
<p style="top:243.3pt;left:333.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 10 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:252.1pt;left:337.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">or 30 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> kg</span></p>
<p style="top:247.7pt;left:393.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after surgery</span></p>
<p style="top:243.3pt;left:486.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">12 weeks after</span></p>
<p style="top:252.1pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:247.7pt;left:566.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology:Pritzker score</span></p>
<p style="top:243.3pt;left:670.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in Pritzker</span></p>
<p style="top:252.1pt;left:666.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">score celecoxib vs. control.</span></p>
<p style="top:282.2pt;left:100.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Ou et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:282.2pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:282.2pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:277.8pt;left:271.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Achilles tendon</span></p>
<p style="top:286.6pt;left:278.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">transection</span></p>
<p style="top:282.2pt;left:333.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 24 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:282.2pt;left:393.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after surgery</span></p>
<p style="top:277.8pt;left:562.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology:Type II collagen</span></p>
<p style="top:286.6pt;left:582.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Tunel staining</span></p>
<p style="top:264.7pt;left:672.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in type II</span></p>
<p style="top:273.5pt;left:663.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">collagen content in celecoxib</span></p>
<p style="top:282.2pt;left:674.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">vs. control, decreased</span></p>
<p style="top:291.0pt;left:669.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">chondrocyte apoptosis in</span></p>
<p style="top:299.8pt;left:683.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">celecoxib group.</span></p>
<p style="top:329.9pt;left:87.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Ashkavand et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:329.9pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:329.9pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:329.9pt;left:289.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">MIA</span></p>
<p style="top:329.9pt;left:331.8pt;line-height:7.1pt"><span style="font-family:URWPalladioL,serif;font-size:7.1pt">Daily 100 mg</span><span style="font-family:Rpxr,serif;font-size:7.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.1pt">kg</span></p>
<p style="top:325.5pt;left:406.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after</span></p>
<p style="top:334.3pt;left:405.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:325.5pt;left:488.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">15 days after</span></p>
<p style="top:334.3pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:325.5pt;left:578.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: Own</span></p>
<p style="top:334.3pt;left:578.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">developed score</span></p>
<p style="top:312.4pt;left:665.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved histological score</span></p>
<p style="top:321.1pt;left:673.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">in the celecoxib group.</span></p>
<p style="top:329.9pt;left:665.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Superior chondroprotective</span></p>
<p style="top:338.7pt;left:670.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">e</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">ects when celecoxib is</span></p>
<p style="top:347.4pt;left:669.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">combined with silymarin</span></p>
<p style="top:377.6pt;left:96.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Moon et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:377.6pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:377.6pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:377.6pt;left:289.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">MIA</span></p>
<p style="top:377.6pt;left:332.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 2.5 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:373.2pt;left:406.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after</span></p>
<p style="top:382.0pt;left:405.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:373.2pt;left:490.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">7 days after</span></p>
<p style="top:382.0pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:377.6pt;left:560.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology:Modi&#xfb01;ed Mankin</span></p>
<p style="top:360.1pt;left:668.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in Modi&#xfb01;ed</span></p>
<p style="top:368.8pt;left:663.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Mankin celecoxib vs. control.</span></p>
<p style="top:377.6pt;left:665.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Synergistic bene&#xfb01;cial action</span></p>
<p style="top:386.4pt;left:681.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">when celecoxib is</span></p>
<p style="top:395.1pt;left:675.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">added to rebamipide</span></p>
<p style="top:412.1pt;left:90.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Panahifar et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:412.1pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:412.1pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:407.7pt;left:272.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">ACLT</span><span style="font-family:Rpxr,serif;font-size:7.2pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> MCLT</span></p>
<p style="top:416.5pt;left:283.8pt;line-height:7.2pt"><span style="font-family:Rpxr,serif;font-size:7.2pt">+</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt"> MMx</span></p>
<p style="top:407.7pt;left:349.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily</span></p>
<p style="top:416.5pt;left:340.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">2.86 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:412.1pt;left:393.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Directly after surgery</span></p>
<p style="top:407.7pt;left:474.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">4,8 and 12 weeks after</span></p>
<p style="top:416.5pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:412.1pt;left:558.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: Modi&#xfb01;ed Mankin</span></p>
<p style="top:407.7pt;left:664.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in histological</span></p>
<p style="top:416.5pt;left:666.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">score celecoxib vs. control.</span></p>
<p style="top:464.2pt;left:111.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Li [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:464.2pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:464.2pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:464.2pt;left:277.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Collagenase</span></p>
<p style="top:464.2pt;left:335.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 0.25 mg</span></p>
<p style="top:464.2pt;left:393.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">6 weeks after surgery</span></p>
<p style="top:459.8pt;left:486.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">10 weeks after</span></p>
<p style="top:468.6pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:451.0pt;left:556.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: Colombo score and</span></p>
<p style="top:459.8pt;left:555.8pt;line-height:7.1pt"><span style="font-family:URWPalladioL,serif;font-size:7.1pt">Biochemistry:CTX-II content in</span></p>
<p style="top:468.6pt;left:560.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">serum, Caspase 3 activity in</span></p>
<p style="top:477.3pt;left:574.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">tissue homogenate</span></p>
<p style="top:429.1pt;left:665.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved histological score</span></p>
<p style="top:437.9pt;left:675.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">in celecoxib group vs.</span></p>
<p style="top:446.6pt;left:674.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">control, higher CTX-II</span></p>
<p style="top:455.4pt;left:666.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">content in celecoxib group,</span></p>
<p style="top:464.2pt;left:666.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">lower Caspase 3 activity in</span></p>
<p style="top:472.9pt;left:683.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">celecoxib group.</span></p>
<p style="top:481.7pt;left:669.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">More pronounced e</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">ects</span></p>
<p style="top:490.5pt;left:664.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">when celecoxib is combined</span></p>
<p style="top:499.2pt;left:686.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">with diacerein</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:742.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5 of 15</span></p>
<p style="top:89.7pt;left:393.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:110.0pt;left:345.3pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Preclinical Studies Using Oral Administration</span></b></p>
<p style="top:127.1pt;left:108.0pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Authors</span></b></p>
<p style="top:127.1pt;left:167.3pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Species</span></b></p>
<p style="top:127.1pt;left:205.5pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">COX-2 Inhibitor</span></b></p>
<p style="top:127.1pt;left:278.9pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA Model</span></b></p>
<p style="top:127.1pt;left:332.2pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Dosing Regime</span></b></p>
<p style="top:127.1pt;left:398.0pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Start of Treatment</span></b></p>
<p style="top:122.8pt;left:487.4pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Timepoint of</span></b></p>
<p style="top:131.5pt;left:491.1pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Evaluation</span></b></p>
<p style="top:122.8pt;left:566.8pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Evaluation of Cartilage</span></b></p>
<p style="top:131.5pt;left:584.1pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Degradation</span></b></p>
<p style="top:127.1pt;left:684.9pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Main Findings</span></b></p>
<p style="top:161.7pt;left:108.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Dai [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:161.7pt;left:174.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Pig</span></p>
<p style="top:161.7pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:161.7pt;left:287.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">MMx</span></p>
<p style="top:161.7pt;left:334.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">20 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg daily</span></p>
<p style="top:161.7pt;left:395.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">1 week after surgery</span></p>
<p style="top:161.7pt;left:473.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">12 weeks after surgery</span></p>
<p style="top:148.5pt;left:571.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Macroscopic:</span><span style="font-family:Rpxr,serif;font-size:7.2pt">|</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OARSI</span></p>
<p style="top:157.3pt;left:568.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">scoreHistology:OARSI</span></p>
<p style="top:166.0pt;left:569.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">scoreCOL-II and AGC</span></p>
<p style="top:174.8pt;left:567.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">immunohistochemistry</span></p>
<p style="top:144.1pt;left:665.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved macroscopic and</span></p>
<p style="top:152.9pt;left:666.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">histological score celecoxib</span></p>
<p style="top:161.7pt;left:681.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">group vs. control,</span></p>
<p style="top:170.4pt;left:665.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">no di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in COL-II and</span></p>
<p style="top:179.2pt;left:683.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">AGC expression</span></p>
<p style="top:200.6pt;left:105.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Nagy [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">23</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:200.6pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:200.6pt;left:214.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Meloxicam</span></p>
<p style="top:200.6pt;left:289.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">MIA</span></p>
<p style="top:196.2pt;left:332.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 0.2 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:205.0pt;left:340.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">or 1 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:196.2pt;left:406.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">3 weeks after</span></p>
<p style="top:205.0pt;left:405.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:196.2pt;left:486.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">11 weeks after</span></p>
<p style="top:205.0pt;left:487.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:200.6pt;left:566.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: OARSI score</span></p>
<p style="top:191.8pt;left:665.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved histological score</span></p>
<p style="top:200.6pt;left:670.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">at both doses meloxicam</span></p>
<p style="top:209.3pt;left:677.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">compared to control</span></p>
<p style="top:226.3pt;left:110.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Tu [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">21</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:226.3pt;left:168.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Mouse</span></p>
<p style="top:226.3pt;left:216.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Celecoxib</span></p>
<p style="top:222.0pt;left:270.5pt;line-height:7.1pt"><span style="font-family:URWPalladioL,serif;font-size:7.1pt">Spontaneous OA</span></p>
<p style="top:230.8pt;left:270.3pt;line-height:7.1pt"><span style="font-family:URWPalladioL,serif;font-size:7.1pt">(STR</span><span style="font-family:Rpxr,serif;font-size:7.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.1pt">Ort mouse)</span></p>
<p style="top:226.3pt;left:335.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Daily 8 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg</span></p>
<p style="top:226.3pt;left:398.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">3 months old mice</span></p>
<p style="top:221.9pt;left:488.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">4 weeks after</span></p>
<p style="top:230.7pt;left:485.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">start treatment</span></p>
<p style="top:226.3pt;left:566.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: OARSI score</span></p>
<p style="top:221.9pt;left:668.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved OARSI score in</span></p>
<p style="top:230.7pt;left:663.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">celecoxib group vs. controls,</span></p>
<p style="top:252.1pt;left:107.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Wen [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:252.1pt;left:174.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Rat</span></p>
<p style="top:252.1pt;left:216.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Etoricoxib</span></p>
<p style="top:252.1pt;left:286.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">ACLT</span></p>
<p style="top:243.3pt;left:337.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">6.7 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg or</span></p>
<p style="top:252.1pt;left:331.8pt;line-height:7.1pt"><span style="font-family:URWPalladioL,serif;font-size:7.1pt">33.3 mg</span><span style="font-family:Rpxr,serif;font-size:7.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.1pt">kg three</span></p>
<p style="top:260.9pt;left:333.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">times per week</span></p>
<p style="top:252.1pt;left:393.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">8 weeks after surgery</span></p>
<p style="top:252.1pt;left:473.2pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">21 weeks after surgery</span></p>
<p style="top:247.7pt;left:565.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: Pritzker score</span></p>
<p style="top:256.5pt;left:585.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">for cartilage</span></p>
<p style="top:243.3pt;left:665.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Improved histological score</span></p>
<p style="top:252.1pt;left:673.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">in the etoricoxib group</span></p>
<p style="top:260.9pt;left:686.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">versus control</span></p>
<p style="top:273.5pt;left:335.7pt;line-height:7.2pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Preclinical Studies Using Intra-Peritoneal Injections</span></b></p>
<p style="top:299.4pt;left:109.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Liu [</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">]</span></p>
<p style="top:299.4pt;left:168.9pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Mouse</span></p>
<p style="top:299.4pt;left:216.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Etoricoxib</span></p>
<p style="top:299.4pt;left:286.8pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">DMM</span></p>
<p style="top:286.3pt;left:344.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">5 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg,</span></p>
<p style="top:295.0pt;left:342.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">10 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg,</span></p>
<p style="top:303.8pt;left:334.0pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">20 mg</span><span style="font-family:Rpxr,serif;font-size:7.2pt">/</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">kg three</span></p>
<p style="top:312.6pt;left:333.5pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">times per week</span></p>
<p style="top:295.0pt;left:409.1pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">2 days after</span></p>
<p style="top:303.8pt;left:405.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">OA induction</span></p>
<p style="top:299.4pt;left:475.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">30 days after surgery</span></p>
<p style="top:299.4pt;left:566.7pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">Histology: OARSI score</span></p>
<p style="top:290.6pt;left:664.4pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.2pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.2pt">erence in histological</span></p>
<p style="top:299.4pt;left:684.3pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">score etoricoxib</span></p>
<p style="top:308.2pt;left:685.6pt;line-height:7.2pt"><span style="font-family:URWPalladioL,serif;font-size:7.2pt">versus control.</span></p>
<p style="top:325.3pt;left:97.8pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">ACLT: Anterior Cruciate Ligament Transection, CLX: celecoxib, DMM: destabilization medial meniscus, ETX: etoricoxib, MCLT: Medial Collateral Ligament Transection, MIAl: Monosodium</span></p>
<p style="top:334.7pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Iodoacetate, MMx: medial meniscectomy, NP: nanoparticle, pMMx: partial medial meniscectomy, PG: proteoglycan.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 of 15</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.2. Preclinical Studies: Intra-Articular Administration</span></i></p>
<p style="top:109.3pt;left:97.7pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Next to</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> studies investigating chondroprotective actions of selective COX-2 inhibitors</span></p>
<p style="top:122.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">administered orally, seven studies focused on their chondroprotective actions when used intra-articularly</span></p>
<p style="top:136.3pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(Table</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">). These studies evaluated several selective COX-2 inhibitors such as celecoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">],</span></p>
<p style="top:149.8pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">parecoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], meloxicam [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] and etoricoxib [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. All studies used surgically induced OA models.</span></p>
<p style="top:163.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Chondroprotective actions, as evidenced by improved histological scores, were shown in three studies</span></p>
<p style="top:177.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">after intra-articular administration with selective COX-2 inhibitors [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Four studies investigated</span></p>
<p style="top:190.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">chondroprotective actions of selective COX-2 inhibitors when incorporated in a drug delivery system</span></p>
<p style="top:203.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(DDS). Dong et al. used celecoxib-loaded liposomes or liposomes loaded with a combination of</span></p>
<p style="top:217.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">celecoxib and hyaluronic acid to study OA-related cartilage damage in a surgically induced rabbit</span></p>
<p style="top:231.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">OA model [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. No di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erence in histological scores was reported when rats received celecoxib-loaded</span></p>
<p style="top:244.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">liposomes, while liposomes loaded with both celecoxib and hyaluronic acid exerted a chondroprotective</span></p>
<p style="top:258.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect compared to control injections [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:271.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">In an earlier study [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], our group has investigated chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects of celecoxib-loaded</span></p>
<p style="top:284.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">polyesteramide (PEA) microspheres in a surgically induced rat OA model. While celecoxib-loaded</span></p>
<p style="top:298.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">microspheres reduced PGE</span><span style="font-family:URWPalladioL,serif;font-size:7.6pt">2</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> as measured in homogenates from knees in this experiment, we could</span></p>
<p style="top:312.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">not &#xfb01;nd chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of celecoxib-loaded PEA microspheres as measured by the OARSI</span></p>
<p style="top:325.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">score [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In another study, Tellegen et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] evaluated e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects of the aforementioned celecoxib-loaded</span></p>
<p style="top:339.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">PEA microspheres on cartilage degeneration in a surgically induced rat OA model. Consistent with our</span></p>
<p style="top:352.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">study, no chondroprotective action of celecoxib-loaded PEA microspheres was observed. In contrast to</span></p>
<p style="top:366.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the &#xfb01;ndings of the aforementioned two studies, one study investigating controlled release of etoricoxib</span></p>
<p style="top:379.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">demonstrated chondroprotective actions as evidenced by improved histological scores compared to</span></p>
<p style="top:393.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">controls [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:406.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In conclusion, when used intra-articularly, three studies report chondroprotective actions of</span></p>
<p style="top:420.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">selective COX-2 inhibitors. On the other hand, there is con&#xfb02;icting evidence regarding chondroprotective</span></p>
<p style="top:433.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">actions of selective COX-2 inhibitors incorporated in intra-articular drug delivery systems: two studies</span></p>
<p style="top:447.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">failed to demonstrate chondroprotective actions, one study shows chondroprotective actions only</span></p>
<p style="top:460.6pt;left:76.1pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">when celecoxib is combined with HA and one study demonstrated chondroprotective activity.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:742.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7 of 15</span></p>
<p style="top:89.7pt;left:157.9pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The schematic of studies investigating chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ects of intra-articularly administered selective COX-2 inhibitors.</span></p>
<p style="top:109.8pt;left:375.8pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Preclinical Studies Using Intra-Articular Injections</span></b></p>
<p style="top:122.1pt;left:105.8pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Authors</span></b></p>
<p style="top:122.1pt;left:160.2pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Species</span></b></p>
<p style="top:122.1pt;left:196.9pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">COX-2 Inhibitor</span></b></p>
<p style="top:122.1pt;left:267.6pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">OA Model</span></b></p>
<p style="top:122.1pt;left:327.2pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Dosing Regime</span></b></p>
<p style="top:122.1pt;left:396.1pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Start of Treatment</span></b></p>
<p style="top:122.1pt;left:464.2pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Timepoint of Evaluation</span></b></p>
<p style="top:122.1pt;left:552.9pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Evaluation of Cartilage Damage</span></b></p>
<p style="top:122.1pt;left:686.0pt;line-height:6.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Main Findings</span></b></p>
<p style="top:142.9pt;left:97.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Jean et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:142.9pt;left:166.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rat</span></p>
<p style="top:142.9pt;left:207.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Parecoxib</span></p>
<p style="top:142.9pt;left:275.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span></p>
<p style="top:134.5pt;left:329.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Weekly 100</span><span style="font-family:EURM10,serif;font-size:6.9pt"> &#xb5;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">g</span></p>
<p style="top:142.9pt;left:331.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">parecoxib for</span></p>
<p style="top:151.3pt;left:320.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">5 consecutive weeks</span></p>
<p style="top:138.7pt;left:405.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Eight weeks</span></p>
<p style="top:147.1pt;left:404.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">after surgery</span></p>
<p style="top:142.9pt;left:468.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">20 weeks after surgery</span></p>
<p style="top:142.9pt;left:565.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: Mankin score</span></p>
<p style="top:134.5pt;left:665.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Improved histological scores</span></p>
<p style="top:142.9pt;left:674.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in the parecoxib group</span></p>
<p style="top:151.3pt;left:677.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">compared to controls</span></p>
<p style="top:171.9pt;left:95.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Jiang et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:171.9pt;left:162.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rabbit</span></p>
<p style="top:171.9pt;left:207.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Celecoxib</span></p>
<p style="top:167.7pt;left:263.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span><span style="font-family:Rpxr,serif;font-size:6.9pt">+</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> PCLT</span></p>
<p style="top:176.1pt;left:272.3pt;line-height:6.9pt"><span style="font-family:Rpxr,serif;font-size:6.9pt">+</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> MMx</span></p>
<p style="top:163.5pt;left:329.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Weekly 1.2 mg</span></p>
<p style="top:171.9pt;left:332.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">celecoxib for</span></p>
<p style="top:180.4pt;left:320.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">5 consecutive weeks</span></p>
<p style="top:167.7pt;left:412.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Directly</span></p>
<p style="top:176.1pt;left:404.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">after surgery</span></p>
<p style="top:171.9pt;left:468.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">12 weeks after surgery</span></p>
<p style="top:171.9pt;left:565.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: Mankin score</span></p>
<p style="top:163.5pt;left:665.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Improved histological scores</span></p>
<p style="top:171.9pt;left:674.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in the Celecoxib group</span></p>
<p style="top:180.4pt;left:677.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">compared to controls</span></p>
<p style="top:205.1pt;left:95.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Dong et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:205.1pt;left:166.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rat</span></p>
<p style="top:205.1pt;left:207.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Celecoxib</span></p>
<p style="top:200.9pt;left:261.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span><span style="font-family:Rpxr,serif;font-size:6.9pt">+</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> PCLT</span><span style="font-family:Rpxr,serif;font-size:6.9pt">+</span></p>
<p style="top:209.4pt;left:262.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">MCLT</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> MMx</span></p>
<p style="top:196.7pt;left:327.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Single injection:</span></p>
<p style="top:205.1pt;left:325.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">0.15 mg celecoxib</span></p>
<p style="top:213.6pt;left:320.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">incorporated in DDS</span></p>
<p style="top:200.9pt;left:409.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">One week</span></p>
<p style="top:209.4pt;left:404.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">after surgery</span></p>
<p style="top:205.1pt;left:470.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">2 weeks after surgery</span></p>
<p style="top:205.1pt;left:563.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: Colombo score</span></p>
<p style="top:192.5pt;left:667.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Improved histological score</span></p>
<p style="top:200.9pt;left:675.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">only when celecoxib is</span></p>
<p style="top:209.4pt;left:665.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">combined with HA in a DDS</span></p>
<p style="top:217.8pt;left:677.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">compared to controls</span></p>
<p style="top:238.4pt;left:96.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Wen et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:238.4pt;left:166.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rat</span></p>
<p style="top:238.4pt;left:205.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Meloxicam</span></p>
<p style="top:238.4pt;left:275.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span></p>
<p style="top:229.9pt;left:320.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Weekly 0.25 or 1 mg</span></p>
<p style="top:238.4pt;left:329.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">meloxicam for</span></p>
<p style="top:246.8pt;left:320.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">5 consecutive weeks</span></p>
<p style="top:234.2pt;left:407.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Five weeks</span></p>
<p style="top:242.6pt;left:404.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">after surgery</span></p>
<p style="top:238.4pt;left:468.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">20 weeks after surgery</span></p>
<p style="top:238.4pt;left:565.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: Pritzker score</span></p>
<p style="top:229.9pt;left:668.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Lower Pritzker score in the</span></p>
<p style="top:238.4pt;left:682.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">meloxicam group</span></p>
<p style="top:246.8pt;left:687.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">versus control</span></p>
<p style="top:267.4pt;left:92.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Janssen et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:267.4pt;left:166.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rat</span></p>
<p style="top:267.4pt;left:207.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Celecoxib</span></p>
<p style="top:267.4pt;left:260.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> pMMx</span></p>
<p style="top:259.0pt;left:327.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Single injection:</span></p>
<p style="top:267.4pt;left:323.2pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">0.015 mg celecoxib</span></p>
<p style="top:275.8pt;left:320.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">incorporated in DDS</span></p>
<p style="top:263.2pt;left:406.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Four weeks</span></p>
<p style="top:271.6pt;left:404.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">after surgery</span></p>
<p style="top:267.4pt;left:468.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">16 weeks after surgery</span></p>
<p style="top:267.4pt;left:566.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: OARSI score</span></p>
<p style="top:259.0pt;left:666.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">No di</span><span style="font-family:Rpxr,serif;font-size:6.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">erence in histological</span></p>
<p style="top:267.4pt;left:671.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">score in celecoxib loaded</span></p>
<p style="top:275.8pt;left:671.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">microspheres vs. control</span></p>
<p style="top:300.6pt;left:90.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Tellegen et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:300.6pt;left:166.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rat</span></p>
<p style="top:300.6pt;left:207.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Celecoxib</span></p>
<p style="top:300.6pt;left:260.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span><span style="font-family:Rpxr,serif;font-size:6.9pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt"> pMMx</span></p>
<p style="top:288.0pt;left:318.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Single injection: 0.015,</span></p>
<p style="top:296.4pt;left:325.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">0.115 or 0.195 mg</span></p>
<p style="top:304.8pt;left:337.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">celecoxib</span></p>
<p style="top:313.3pt;left:320.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">incorporated in DDS</span></p>
<p style="top:296.4pt;left:406.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Four weeks</span></p>
<p style="top:304.8pt;left:404.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">after surgery</span></p>
<p style="top:300.6pt;left:468.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">16 weeks after surgery</span></p>
<p style="top:300.6pt;left:566.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: OARSI score</span></p>
<p style="top:292.2pt;left:666.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">No di</span><span style="font-family:Rpxr,serif;font-size:6.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">erence in histological</span></p>
<p style="top:300.6pt;left:671.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">score in celecoxib loaded</span></p>
<p style="top:309.1pt;left:671.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">microspheres vs. control</span></p>
<p style="top:342.3pt;left:98.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Liu et al. [</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">]</span></p>
<p style="top:342.3pt;left:166.9pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Rat</span></p>
<p style="top:342.3pt;left:207.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Etoricoxib</span></p>
<p style="top:342.3pt;left:275.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ACLT</span></p>
<p style="top:325.4pt;left:327.1pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Three injections:</span></p>
<p style="top:333.9pt;left:319.6pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">- 10</span><span style="font-family:EURM10,serif;font-size:6.9pt"> &#xb5;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">M etoricoxib in</span></p>
<p style="top:342.3pt;left:319.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">100</span><span style="font-family:EURM10,serif;font-size:6.9pt"> &#xb5;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">L NaCl- 6.93</span><span style="font-family:EURM10,serif;font-size:6.9pt"> &#xb5;</span><span style="font-family:URWPalladioL,serif;font-size:6.9pt">g</span></p>
<p style="top:350.7pt;left:328.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">ETX-NPs, drug</span></p>
<p style="top:359.2pt;left:327.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">loading unclear</span></p>
<p style="top:338.1pt;left:395.5pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Three, six and nine</span></p>
<p style="top:346.5pt;left:394.3pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">weeks after surgery</span></p>
<p style="top:342.3pt;left:468.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">12 weeks after surgery</span></p>
<p style="top:338.1pt;left:566.8pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Histology: OARSI score</span></p>
<p style="top:346.5pt;left:567.4pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Immunohistochemistry</span></p>
<p style="top:333.9pt;left:667.0pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">Improved histological score</span></p>
<p style="top:342.3pt;left:672.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">in ETX-NP, but not ETX,</span></p>
<p style="top:350.7pt;left:677.7pt;line-height:6.9pt"><span style="font-family:URWPalladioL,serif;font-size:6.9pt">compared to control.</span></p>
<p style="top:371.4pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">ACLT: Anterior Cruciate Ligament Transection, CLX: celecoxib, DDS: drug delivery system, ETX: etoricoxib, HA: hyaluronic acid, MCLT: Medial Collateral Ligament Transection,</span></p>
<p style="top:380.9pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">MMS: modi&#xfb01;ed mankin score, MMx: medial meniscectomy, NP: nanoparticle, pMMx: partial medial meniscectomy.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8 of 15</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2.3. Clinical Studies</span></i></p>
<p style="top:109.4pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Four clinical studies investigated chondroprotective actions of selective COX-2 inhibitors via oral</span></p>
<p style="top:123.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">administration, while there were no studies investigating chondroprotective actions of selective COX-2</span></p>
<p style="top:136.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">inhibitors after intra-articular administration (Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 3</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">).</span></p>
<p style="top:149.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Tindall et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] included patients diagnosed with knee OA in a prospective open-label trial.</span></p>
<p style="top:163.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Patients with OA received celecoxib orally at two dosages throughout a 12-month study period.</span></p>
<p style="top:177.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Long-term celecoxib treatment did not result in signi&#xfb01;cant changes of joint space width (JSW) at 1 year</span></p>
<p style="top:190.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">after treatment as assessed radiographically. Moreover, when radiographic knee OA progression</span></p>
<p style="top:203.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">during the study was compared to radiographic knee OA progression prior to the start of the study,</span></p>
<p style="top:217.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">no signi&#xfb01;cant di</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">erences were detected [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:230.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Sawitzke et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] conducted a placebo-controlled study of patients with knee OA in which</span></p>
<p style="top:244.5pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">patients received placebo or celecoxib orally on a daily basis. No signi&#xfb01;cant di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erences were found in</span></p>
<p style="top:257.9pt;left:76.4pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">JSW loss compared to placebo at 24 months, while Kellgren and Lawrence grade 2 knees showed a</span></p>
<p style="top:271.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">trend towards less JSW loss. In contrast to the &#xfb01;ndings of the aforementioned clinical studies, a study</span></p>
<p style="top:285.1pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">performed by de Boer et al. suggested that celecoxib might exert chondroprotective actions [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. In this</span></p>
<p style="top:298.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">study, patients with end-stage knee OA were treated with orally supplemented celecoxib 28 days</span></p>
<p style="top:312.0pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">prior to total knee replacement surgery. Compared to patients that did not receive celecoxib, cartilage</span></p>
<p style="top:325.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">samples of patients that received celecoxib showed increased proteoglycan (PG) synthesis, decreased</span></p>
<p style="top:339.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">PG release and an increased PG content.</span></p>
<p style="top:352.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Raynould et al. conducted a study in which patients with knee OA were enrolled receiving</span></p>
<p style="top:366.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">celecoxib orally throughout a 12-month study period [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. After correcting for potential confounders,</span></p>
<p style="top:379.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">celecoxib treatment did not show any protective e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect on cartilage volume loss compared to a historical</span></p>
<p style="top:393.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">knee OA cohort loss, as assessed by quantitative MRI.</span></p>
<p style="top:406.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In conclusion, evidence of chondroprotective actions of selective COX-2 inhibitors in human</span></p>
<p style="top:420.0pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">patients is low, since three human</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> studies failed to show chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects of orally</span></p>
<p style="top:433.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">administered celecoxib, while only one study suggests that celecoxib may act chondroprotective</span></p>
<p style="top:447.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in humans.</span></p>
<p style="top:460.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The selectivity of the COX-2 inhibitors that were used in the preclinical and clinical studies</span></p>
<p style="top:474.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">described in this review has been compared by Riendeau et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The COX-2 selectivity may play</span></p>
<p style="top:487.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a role in the chondroprotective outcome of a selective COX-2 inhibitor, but the number of studies</span></p>
<p style="top:501.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">described in this systematic review was too small to draw any conclusions. An overview of the</span></p>
<p style="top:514.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">half maximal inhibitory concentration (IC</span><span style="font-family:URWPalladioL,serif;font-size:7.6pt">50</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">) values for COX-1 and COX-2 of these selective COX-2</span></p>
<p style="top:528.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">inhibitors together with the COX-1</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">COX-2 IC</span><span style="font-family:URWPalladioL,serif;font-size:7.6pt">50</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> ratio is provided in Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:742.4pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 of 15</span></p>
<p style="top:89.7pt;left:130.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 3.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The schematic overview of clinical studies investigating chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ects of systemically administered selective COX-2 inhibitors.</span></p>
<p style="top:110.1pt;left:347.0pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Clinical Studies Using Oral Administration</span></b></p>
<p style="top:123.4pt;left:109.2pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Authors</span></b></p>
<p style="top:123.4pt;left:172.7pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Species</span></b></p>
<p style="top:123.4pt;left:214.2pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">COX-2 Inhibitor</span></b></p>
<p style="top:123.4pt;left:284.1pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">OA Grade</span></b></p>
<p style="top:123.4pt;left:343.7pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Dosing Regime</span></b></p>
<p style="top:123.4pt;left:419.9pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Treatment Duration</span></b></p>
<p style="top:123.4pt;left:506.5pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Evaluation of Cartilage Damage</span></b></p>
<p style="top:123.4pt;left:659.5pt;line-height:7.4pt"><b><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Chondroprotection</span></b></p>
<p style="top:150.3pt;left:95.2pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Tindall et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">]</span></p>
<p style="top:150.3pt;left:172.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Human</span></p>
<p style="top:150.3pt;left:226.0pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Celecoxib</span></p>
<p style="top:150.3pt;left:280.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">K&amp;L 2 and 3</span></p>
<p style="top:150.3pt;left:337.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Daily 200 or 400 mg</span></p>
<p style="top:150.3pt;left:436.4pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">12 months</span></p>
<p style="top:150.3pt;left:520.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Radiographs of the knee</span></p>
<p style="top:136.6pt;left:635.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.4pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">erence in JSW, subchondral</span></p>
<p style="top:145.7pt;left:639.1pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">sclerosis, cysts, malalignment or</span></p>
<p style="top:154.8pt;left:634.5pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">tilting after 12 months of treatment</span></p>
<p style="top:163.9pt;left:668.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">with celecoxib</span></p>
<p style="top:181.5pt;left:91.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Sawitzke et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">]</span></p>
<p style="top:181.5pt;left:172.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Human</span></p>
<p style="top:181.5pt;left:226.0pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Celecoxib</span></p>
<p style="top:181.5pt;left:280.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">K&amp;L 2 and 3</span></p>
<p style="top:181.5pt;left:348.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Daily 200 mg</span></p>
<p style="top:181.5pt;left:436.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">24 months</span></p>
<p style="top:181.5pt;left:520.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Radiographs of the knee</span></p>
<p style="top:177.0pt;left:631.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">No signi&#xfb01;cant di</span><span style="font-family:Rpxr,serif;font-size:7.4pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">erences in JSW loss</span></p>
<p style="top:186.1pt;left:652.8pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">in celecoxib vs. controls</span></p>
<p style="top:221.9pt;left:93.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">De Boer et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">]</span></p>
<p style="top:221.9pt;left:172.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Human</span></p>
<p style="top:221.9pt;left:226.0pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Celecoxib</span></p>
<p style="top:221.9pt;left:279.7pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Not speci&#xfb01;ed</span></p>
<p style="top:221.9pt;left:348.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Daily 200 mg</span></p>
<p style="top:221.9pt;left:440.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">4 weeks</span></p>
<p style="top:212.8pt;left:505.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Biochemical cartilage analysis:PG</span></p>
<p style="top:221.9pt;left:519.1pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">synthesis rate, PG release</span></p>
<p style="top:231.0pt;left:535.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">and PG content</span></p>
<p style="top:199.2pt;left:646.4pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Increased PG synthesis rate,</span></p>
<p style="top:208.3pt;left:633.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">decreased PG release and increased</span></p>
<p style="top:217.4pt;left:631.7pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">PG content in the celecoxib group vs.</span></p>
<p style="top:226.5pt;left:636.5pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">controls. Decreased release of il-1,</span></p>
<p style="top:235.6pt;left:631.1pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">TNF-</span><span style="font-family:EURM10,serif;font-size:7.4pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt"> and mmp-activity in celecoxib</span></p>
<p style="top:244.7pt;left:663.6pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">group vs. control</span></p>
<p style="top:266.8pt;left:90.7pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Raynauld et al. [</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">]</span></p>
<p style="top:266.8pt;left:172.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Human</span></p>
<p style="top:266.8pt;left:226.0pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Celecoxib</span></p>
<p style="top:266.8pt;left:280.9pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">K&amp;L 2 and 3</span></p>
<p style="top:266.8pt;left:348.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Daily 200 mg</span></p>
<p style="top:266.8pt;left:436.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">12 months</span></p>
<p style="top:266.8pt;left:531.8pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">Quantitative MRI</span></p>
<p style="top:257.8pt;left:631.3pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">No di</span><span style="font-family:Rpxr,serif;font-size:7.4pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:7.4pt">erence in cartilage volume loss</span></p>
<p style="top:266.8pt;left:637.0pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">in celecoxib group vs. a historical</span></p>
<p style="top:275.9pt;left:658.0pt;line-height:7.4pt"><span style="font-family:URWPalladioL,serif;font-size:7.4pt">cohort control group</span></p>
<p style="top:289.0pt;left:292.7pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">JSW: Joint space width, K&amp;L: Kellgren and Lawrence, PG: proteoglycan.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 of 15</span></p>
<p style="top:89.7pt;left:97.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 4.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> The schematic overview of the half maximal inhibitory concentration (IC</span><span style="font-family:URWPalladioL,serif;font-size:7.0pt">50</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">) values and the</span></p>
<p style="top:102.5pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-1</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-2 IC</span><span style="font-family:URWPalladioL,serif;font-size:7.0pt">50</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> ratio of various selective COX-2 inhibitors. Adapted from [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">].</span></p>
<p style="top:123.6pt;left:139.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug</span></b></p>
<p style="top:123.6pt;left:192.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IC50 COX-1 (</span></b><b><span style="font-family:EURB10,serif;font-size:9.0pt">&#xb5;</span></b><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">M)</span></b></p>
<p style="top:123.6pt;left:281.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IC50 COX-2 (</span></b><b><span style="font-family:EURB10,serif;font-size:9.0pt">&#xb5;</span></b><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">M)</span></b></p>
<p style="top:123.6pt;left:369.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-1</span></b><span style="font-family:Rpxb,serif;font-size:9.0pt">/</span><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX-2 IC</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.0pt">50</span></b><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Ratio</span></b></p>
<p style="top:139.6pt;left:127.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Meloxicam</span></p>
<p style="top:139.6pt;left:222.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.4</span></p>
<p style="top:139.6pt;left:311.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">0.7</span></p>
<p style="top:139.6pt;left:418.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2</span></p>
<p style="top:150.8pt;left:130.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Celecoxib</span></p>
<p style="top:150.8pt;left:222.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">6.7</span></p>
<p style="top:150.8pt;left:309.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">0.87</span></p>
<p style="top:150.8pt;left:414.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7.7</span></p>
<p style="top:162.0pt;left:129.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Etoricoxib</span></p>
<p style="top:162.0pt;left:221.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">116</span></p>
<p style="top:162.0pt;left:311.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.1</span></p>
<p style="top:162.0pt;left:413.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">105</span></p>
<p style="top:173.2pt;left:130.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Parecoxib</span></p>
<p style="top:173.2pt;left:220.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">26.1</span></p>
<p style="top:173.2pt;left:309.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">0.87</span></p>
<p style="top:173.2pt;left:415.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">30</span></p>
<p style="top:201.6pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3. Discussion</span></b></p>
<p style="top:221.1pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The main &#xfb01;nding of this systematic review is that the administration route plays a major role in</span></p>
<p style="top:234.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">determining chondroprotective actions of selective COX-2 inhibitors. The intra-articular administration</span></p>
<p style="top:248.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">route may be promising, since studies using bolus intra-articular administration of selective COX-2</span></p>
<p style="top:261.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibitors show chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects. On the other hand, con&#xfb02;icting evidence exists when selective</span></p>
<p style="top:275.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">COX-2 inhibitors are incorporated into a drug delivery system. While preclinical studies point out</span></p>
<p style="top:288.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">to a potential chondroprotective role of COX-2 inhibitors, clinical studies did not investigate the</span></p>
<p style="top:302.1pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">intra-articular administration route and failed to con&#xfb01;rm chondroprotective actions of systemically</span></p>
<p style="top:315.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">administered selective COX-2 inhibitors.</span></p>
<p style="top:329.3pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Discrepancies in chondroprotective actions of selective COX-2 inhibitors observed in the preclinical</span></p>
<p style="top:342.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">studies may be related to the route of administration. While six of the fourteen studies using systemic</span></p>
<p style="top:356.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">administration failed to demonstrate chondroprotective actions of selective COX-2 inhibitors, all studies</span></p>
<p style="top:369.6pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">that applied intra-articular bolus injections demonstrated chondroprotective actions. Interestingly,</span></p>
<p style="top:383.2pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">all clinical studies included in this systematic review evaluated chondroprotective actions using</span></p>
<p style="top:396.7pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the systemic administration route.</span></p>
<p style="top:396.7pt;left:242.4pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Since these studies failed to demonstrate chondroprotective</span></p>
<p style="top:410.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">actions, it will be of interest to investigate the chondroprotective actions of selective COX-2 inhibitors</span></p>
<p style="top:423.7pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">using the intra-articular administration route for clinical studies. We did not encounter studies</span></p>
<p style="top:437.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">comparing chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of systemic versus intra-articularly administration of selective</span></p>
<p style="top:450.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">COX-2 inhibitors, but we believe this will be of interest to investigate in the future.</span></p>
<p style="top:464.4pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Improved chondroprotection of intra-articular injections with selective COX-2 inhibitor compared</span></p>
<p style="top:477.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">to a saline control condition may be related to increased bioavailability of the drug in the knee joint</span></p>
<p style="top:491.2pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">compared to systemic administrations. In addition, in a total joint disease such as knee OA [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">],</span></p>
<p style="top:504.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">intra-articular administration of drugs may be more e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ective compared to systemic treatment due to</span></p>
<p style="top:518.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the presence of scarcely vascularized tissues such as cartilage and meniscus [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Since COX-2 inhibitors</span></p>
<p style="top:531.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">can have an e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect on all joint tissues, it is unclear whether the chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect is a direct result</span></p>
<p style="top:545.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">of COX-2 inhibition in chondrocytes or an e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of COX-2 inhibition of other joint tissues.</span></p>
<p style="top:558.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Others and we failed to show a reduction of OA-related cartilage damage by celecoxib,</span></p>
<p style="top:572.4pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">when incorporated in an intra-articular drug delivery system [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. It is a possibility that prolonged</span></p>
<p style="top:585.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">release of celecoxib may counteract potential chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects due to increased loading of the</span></p>
<p style="top:599.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">a</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ected joint indirectly caused by the analgesic e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects of COX-2 inhibitors. These &#xfb01;ndings corroborate</span></p>
<p style="top:612.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">earlier observations in clinical studies, in which patients treated with anti-NGF demonstrated an</span></p>
<p style="top:626.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">increase in OA-related cartilage damage possibly due to joint overloading [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:639.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">COX-2 inhibitors are expected to have anti-in&#xfb02;ammatory e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects by inhibiting the synthesis of</span></p>
<p style="top:653.4pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">prostanoids. Prostanoid subtypes are considered as in&#xfb02;ammatory mediators [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] and are involved in</span></p>
<p style="top:667.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">cartilage degradation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], but also in other pathophysiologic OA processes in di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent joint tissues such</span></p>
<p style="top:680.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">as synovial &#xfb01;brosis and chondrocyte hypertrophy [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. However, also anti-in&#xfb02;ammatory actions of</span></p>
<p style="top:694.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">certain prostanoid subtypes have been shown [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], and therefore identifying downstream targets of the</span></p>
<p style="top:707.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">COX-2 pathway may further aid in anti-in&#xfb02;ammatory treatment for knee OA. In&#xfb02;ammatory processes</span></p>
<p style="top:721.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">have been suggested to precede knee OA [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] and to be involved in structural disease progression [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">].</span></p>
<p style="top:734.4pt;left:76.1pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">A window of opportunity may exist, in which modulating the in&#xfb02;ammatory status of the knee joint</span></p>
<p style="top:747.9pt;left:76.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">via intra-articular treatment with selective COX-2 inhibitors may lead to OA disease modi&#xfb01;cation.</span></p>
<p style="top:761.5pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">The initiation of treatment may thus be important for the treatment outcome. The studies performed</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11 of 15</span></p>
<p style="top:89.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">by Wen et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] and Dai et al. [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] did not start treatment shortly after surgery and demonstrated</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">chondroprotective actions of orally administered COX-2 inhibitors. It can be hypothesized that</span></p>
<p style="top:117.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibiting in&#xfb02;ammation directly after inducing a joint trauma may compromise cartilage regeneration,</span></p>
<p style="top:130.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">since in&#xfb02;ammation is part of the early phases of natural tissue regeneration after a trauma [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:143.8pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">This may explain why studies in surgical OA models fail to show chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects when</span></p>
<p style="top:157.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">starting treatment directly after surgery. Moreover, the lack of a chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect in clinical</span></p>
<p style="top:170.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">studies may be related to the stage of disease. Patients with knee OA are diagnosed in a stadium</span></p>
<p style="top:184.4pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">when the disease has progressed towards its end-stage [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], and it can be hypothesized that at</span></p>
<p style="top:197.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">this stage the disease is in an irreversible stadium where drug-based disease modi&#xfb01;cation is not</span></p>
<p style="top:211.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ective anymore. In addition, knee OA is a heterogeneous disease showing variability in the rate</span></p>
<p style="top:224.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">of disease progression in human subjects [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], while also the existence of distinct OA subtypes</span></p>
<p style="top:238.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">has been suggested [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">48</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], suggesting that patient-tailored drug treatment needs to be developed.</span></p>
<p style="top:252.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Finally, the outcome measurements of clinical studies, such as joint space narrowing on conventional</span></p>
<p style="top:265.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">radiography, may not be sensitive enough. With the ongoing advancements in cartilage imaging [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">49</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">],</span></p>
<p style="top:279.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">advanced techniques such as 7-tesla MRI imaging [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">49</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">] may provide a more sensitive means to evaluate</span></p>
<p style="top:292.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">multiple outcome domains relevant to the clinical and pathophysiological aspects of disease modifying</span></p>
<p style="top:306.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">osteoarthritis drug (DMOAD)-mediated disease modi&#xfb01;cation.</span></p>
<p style="top:329.2pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4. Materials and Methods</span></b></p>
<p style="top:352.5pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.1. Search Strategy and Data Extraction</span></i></p>
<p style="top:371.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">MEDLINE and EMBASE databases were systematically searched on all studies relating</span></p>
<p style="top:385.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">intra-articular or oral treatment of knee OA patients with selective COX-2 inhibitors. The search was</span></p>
<p style="top:399.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">conducted in May 2020 according to the search strategy and data collection guidelines of the preferred</span></p>
<p style="top:412.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">reporting items for systematic reviews and meta-analyses (PRISMA) statement. A manual search of</span></p>
<p style="top:426.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the Cochrane library yielded no relevant articles. Upon reading the full-text key papers snowballing</span></p>
<p style="top:439.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">searching manually reference lists of the included articles was allowed. Disagreements between the</span></p>
<p style="top:453.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">reviewers were resolved by consensus.</span></p>
<p style="top:466.5pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">After disregarding duplicates, the title and the abstract of articles were independently screened</span></p>
<p style="top:480.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">by two observers according to prede&#xfb01;ned criteria. The search query was as follows:</span></p>
<p style="top:493.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(&#x201c;Osteoarthritis&#x201d;[Mesh] OR OA OR osteoarthritis) AND (&#x201c;Knee&#x201d;[Mesh] OR Knee [tiab]) AND</span></p>
<p style="top:507.0pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(((COX-2 [tiab] OR COX2 [tiab] OR Cyclooxygenase 2 [tiab] OR&#x201d;Cyclooxygenase 2&#x201d;[Mesh]) AND</span></p>
<p style="top:520.5pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(inhibitor [tiab] or inhibition [tiab] or limitation [tiab] or limiting [tiab])) OR celecoxib [tiab] OR</span></p>
<p style="top:534.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">etoricoxib [tiab] OR rofecoxib [tiab] or valdecoxib [tiab] or lumiracoxib [tiab] or mavacoxib [tiab] or</span></p>
<p style="top:547.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">meloxicam [tiab] or VA441 [tiab] or MK-0966 [tiab] or gw406381 [tiab] or SC-58635 [tiab] or VA692</span></p>
<p style="top:561.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">[tiab] or VA694 [tiab] or SC-236 [tiab]) AND ((oral [tiab] AND (suppletion [tiab] OR supplements [tiab]</span></p>
<p style="top:574.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">OR supplementation [tiab] OR treatment [tiab] OR ingestion [tiab] OR medication [tiab] OR tablets</span></p>
<p style="top:588.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">[tiab] OR intake [tiab] OR absorption [tiab])) OR treatment OR ((intraarticular [tiab] OR intra-articular</span></p>
<p style="top:601.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">[tiab]) AND (injection [tiab] OR therapy [tiab] OR supplementation [tiab] OR suppletion [tiab]))).</span></p>
<p style="top:624.8pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.2. Articles Were Selected Based on Inclusion and Exclusion Criteria</span></i></p>
<p style="top:644.3pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Inclusion criteria:</span></p>
<p style="top:665.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">i.</span></p>
<p style="top:665.7pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Presenting data about chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of COX-2 inhibitors; The chondroprotective</span></p>
<p style="top:679.2pt;left:108.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect is de&#xfb01;ned as any e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect that leads to signi&#xfb01;cantly less cartilage degradation evidenced</span></p>
<p style="top:692.8pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">either through imaging, biochemical analysis or on histology.</span></p>
<p style="top:707.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ii.</span></p>
<p style="top:707.3pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Either in vivo animal studies or clinical studies involving human knee OA patients;</span></p>
<p style="top:721.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">iii.</span></p>
<p style="top:721.8pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Intra-articular therapies with COX-2 inhibitors;</span></p>
<p style="top:736.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">iv.</span></p>
<p style="top:736.3pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Systemic therapies with COX-2 inhibitors.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 of 15</span></p>
<p style="top:89.9pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Exclusion criteria:</span></p>
<p style="top:109.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">i.</span></p>
<p style="top:109.3pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Studies solely investigating non-selective cox-inhibitors;</span></p>
<p style="top:123.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ii.</span></p>
<p style="top:123.8pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Studies investigating actions of celecoxib inhibitors on pain modulation in knee OA;</span></p>
<p style="top:138.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">iii.</span></p>
<p style="top:138.3pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Studies investigating other joints than the knee;</span></p>
<p style="top:152.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">iv.</span></p>
<p style="top:152.8pt;left:108.9pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Studies reporting solely in vitro data.</span></p>
<p style="top:172.2pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Two observers systematically extracted study data based on the inclusion and exclusion criteria.</span></p>
<p style="top:185.7pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The risk of bias of the included studies was evaluated using the SYRCLE&#x2019;s risk of bias tool for animal</span></p>
<p style="top:199.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">studies [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">10</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] and the Cochrane risk of bias tool [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">11</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">] for human studies.</span></p>
<p style="top:222.4pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">5. Conclusions</span></b></p>
<p style="top:242.0pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">To date there is con&#xfb02;icting evidence regarding the ability of selective COX-2 inhibitors to be used</span></p>
<p style="top:255.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">as DMOADs. Preclinical studies have used di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent routes of administration, which may alter the</span></p>
<p style="top:269.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">chondroprotective outcome of selective COX-2 inhibitors in the knee joint where scarcely vascularized</span></p>
<p style="top:282.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">tissues are present. Other factors such as the OA model type, type of selective COX-2 inhibitor</span></p>
<p style="top:295.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and disease stage seem also to be involved in the chondroprotective outcome of selective COX-2</span></p>
<p style="top:309.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inhibitors. Despite the limited evidence of data in clinical studies, there seems to be a preclinical basis</span></p>
<p style="top:323.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">for considering selective COX-2 inhibitors as DMOADs speci&#xfb01;cally when used intra-articularly.</span></p>
<p style="top:346.2pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">6. Patents</span></b></p>
<p style="top:365.8pt;left:97.7pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">TJM Welting is listed as inventor on patents: WO2017178251, WO2017178253 and US 20130123314. PJ</span></p>
<p style="top:379.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Emans and LW van Rhijn are listed as inventors on patent US 20130123314. LW van Rhijn, PJ Emans and</span></p>
<p style="top:392.8pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">TJM Welting have shares in Chondropeptix and are CDO, CMO and CSO of Chondropeptix, respectively.</span></p>
<p style="top:415.6pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Supplementary Materials:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Supplementary materials can be found at</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7"> http:</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">www.mdpi.com</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">1422-0067</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">21</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">18</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">6962</span><span style="font-family:Rpxr,serif;font-size:8.9pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">s1</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">.</span></p>
<p style="top:431.7pt;left:76.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Author Contributions:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Conceptualization, U.T.T., M.M.J.C., R.M.J., Y.M.B.-J., T.J.M.W., G.J.V.M.v.O., L.W.v.R.</span></p>
<p style="top:441.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and P.J.E.; methodology U.T.T., M.M.J.C., R.M.J., T.J.M.W., G.J.V.M.v.O. and P.J.E.; formal analysis, U.T.T., R.M.J.,</span></p>
<p style="top:452.0pt;left:76.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">M.M.J.C., T.J.M.W., G.J.V.M.v.O. and P.J.E.; writing&#x2014;original draft preparation, U.T.T.; writing&#x2014;review and editing</span></p>
<p style="top:462.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">U.T.T., M.M.J.C., R.M.J., Y.M.B.-J., L.W.v.R., T.J.M.W., G.J.V.M.v.O. and P.J.E. All authors have read and agreed to</span></p>
<p style="top:472.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">the published version of the manuscript.</span></p>
<p style="top:488.3pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Funding:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> This research was funded by the Dutch Arthritis Foundation (LLP11 and LLP14), the academic fund of</span></p>
<p style="top:498.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Maastricht University Medical Center and the Annadal Foundation.</span></p>
<p style="top:514.6pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Con&#xfb02;icts of Interest:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> The authors declare no con&#xfb02;ict of interest. The funders had no role in the design of the</span></p>
<p style="top:524.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to</span></p>
<p style="top:534.8pt;left:76.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">publish the results.</span></p>
<p style="top:557.3pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Abbreviations</span></b></p>
<p style="top:577.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ACLT</span></p>
<p style="top:577.1pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Anterior cruciate ligament transection</span></p>
<p style="top:589.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CLX</span></p>
<p style="top:589.5pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Celecoxib</span></p>
<p style="top:602.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">COX</span></p>
<p style="top:602.0pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Cyclooxygenase</span></p>
<p style="top:614.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DDS</span></p>
<p style="top:614.4pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Drug Delivery System</span></p>
<p style="top:626.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DMM</span></p>
<p style="top:626.8pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Destabilization of the medial meniscus</span></p>
<p style="top:639.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">DMOAD</span></p>
<p style="top:639.3pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Disease modifying osteoarthritis drugs</span></p>
<p style="top:651.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ETX</span></p>
<p style="top:651.7pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Etoricoxib</span></p>
<p style="top:664.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">HA</span></p>
<p style="top:664.1pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hyaluronic acid</span></p>
<p style="top:676.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">JSW</span></p>
<p style="top:676.6pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Joint space width</span></p>
<p style="top:689.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">K&amp;L</span></p>
<p style="top:689.0pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Kellgren and Lawrence</span></p>
<p style="top:701.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MCLT</span></p>
<p style="top:701.4pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Medial collateral ligament transection</span></p>
<p style="top:713.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MIA</span></p>
<p style="top:713.9pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Monosodiumiodoacetate</span></p>
<p style="top:726.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MMx</span></p>
<p style="top:726.3pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Medial meniscus transection</span></p>
<p style="top:738.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MRI</span></p>
<p style="top:738.7pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Magnetic Resonance Imaging</span></p>
<p style="top:751.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NP</span></p>
<p style="top:751.1pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Nanoparticle</span></p>
<p style="top:763.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NSAID</span></p>
<p style="top:763.6pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Non-steroidal anti-in&#xfb02;ammatory drugs</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">13 of 15</span></p>
<p style="top:89.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">OA</span></p>
<p style="top:89.4pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Osteoarthritis</span></p>
<p style="top:101.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PEA</span></p>
<p style="top:101.9pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Polyesteramide</span></p>
<p style="top:114.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pg</span></p>
<p style="top:114.3pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Prostaglandin</span></p>
<p style="top:126.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PG</span></p>
<p style="top:126.7pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Proteoglycan</span></p>
<p style="top:139.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pMMx</span></p>
<p style="top:139.1pt;left:134.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Partial medial meniscus transection</span></p>
<p style="top:165.1pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">References</span></b></p>
<p style="top:184.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.</span></p>
<p style="top:184.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hunter, D.J.; Felson, D.T. Osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMJ</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 332</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 639&#x2013;642. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:197.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2.</span></p>
<p style="top:197.7pt;left:98.0pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Arterioscler Thromb Vasc. Biol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 31</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 986&#x2013;1000.</span></p>
<p style="top:210.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:223.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3.</span></p>
<p style="top:223.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Martel-Pelletier, J.; Pelletier, J.P.; Fahmi, H. Cyclooxygenase-2 and prostaglandins in articular tissues.</span></p>
<p style="top:236.4pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Semin. Arthritis Rheum.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2003</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 33</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 155&#x2013;167. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:249.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.</span></p>
<p style="top:249.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ayral, X.; Pickering, E.H.; Woodworth, T.G.; Mackillop, N.; Dougados, M. Synovitis: A potential predictive</span></p>
<p style="top:262.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">factor of structural progression of medial tibiofemoral knee osteoarthritis&#x2014;Results of a 1 year longitudinal</span></p>
<p style="top:275.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">arthroscopic study in 422 patients.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2005</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 361&#x2013;367. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:288.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">5.</span></p>
<p style="top:288.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Miller, R.E.; Block, J.A.; Malfait, A.M. Nerve growth factor blockade for the management of osteoarthritis</span></p>
<p style="top:301.0pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">pain: What can we learn from clinical trials and preclinical models?</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Curr. Opin. Rheumatol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 29</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 110&#x2013;118.</span></p>
<p style="top:313.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:326.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">6.</span></p>
<p style="top:326.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Ding, C. Do NSAIDs a</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ect the progression of osteoarthritis?</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> In&#xfb02;ammation</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2002</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 26</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 139&#x2013;142. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:339.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7.</span></p>
<p style="top:339.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Zweers, M.C.; De Boer, T.N.; Van Roon, J.; Bijlsma, J.W.; Lafeber, F.P.; Mastbergen, S.C. Celecoxib:</span></p>
<p style="top:352.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Considerations regarding its potential disease-modifying properties in osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Arthritis Res. Ther.</span></i></p>
<p style="top:365.5pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 13</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 239. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:378.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8.</span></p>
<p style="top:378.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Buckwalter, J.A.; Mankin, H.J. Articular cartilage: Tissue design and chondrocyte-matrix interactions.</span></p>
<p style="top:391.3pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Instr. Course Lect.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1998</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 47</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 477&#x2013;486.</span></p>
<p style="top:404.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9.</span></p>
<p style="top:404.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Makris, E.A.; Hadidi, P.; Athanasiou, K.A. The knee meniscus: Structure-function, pathophysiology, current</span></p>
<p style="top:417.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">repair techniques, and prospects for regeneration.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biomaterials</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 32</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 7411&#x2013;7431. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:430.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10.</span></p>
<p style="top:430.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hooijmans, C.R.; Rovers, M.M.; De Vries, R.B.; Leenaars, M.; Ritskes-Hoitinga, M.; Langendam, M.W.</span></p>
<p style="top:443.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">SYRCLE&#x2019;s risk of bias tool for animal studies.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMC Med. Res. Methodol</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 43. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:455.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11.</span></p>
<p style="top:456.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Van der Kraan, P.M.; Buma, P.; Van Kuppevelt, T.; Van den Berg, W.B. Interaction of chondrocytes, extracellular</span></p>
<p style="top:468.8pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">matrix and growth factors: Relevance for articular cartilage tissue engineering.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2002</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:481.7pt;left:97.6pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 631&#x2013;637. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:494.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">12.</span></p>
<p style="top:494.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mastbergen, S.C.; Marijnissen, A.C.; Vianen, M.E.; Zoer, B.; Van Roermund, P.M.; Bijlsma, J.W.; Lafeber, F.P.</span></p>
<p style="top:507.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Rheumatology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2006</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 45</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 405&#x2013;413.</span></p>
<p style="top:520.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:533.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">13.</span></p>
<p style="top:533.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Huh, J.E.; Baek, Y.H.; Kim, Y.J.; Lee, J.D.; Choi, D.Y.; Park, D.S. Protective e</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ects of butanol fraction from</span></p>
<p style="top:546.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Betula platyphyla var. japonica on cartilage alterations in a rabbit collagenase-induced osteoarthritis.</span></p>
<p style="top:559.2pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">J. Ethnopharmacol</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 123</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 515&#x2013;521. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:572.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">14.</span></p>
<p style="top:572.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Fukai, A.; Kamekura, S.; Chikazu, D.; Nakagawa, T.; Hirata, M.; Saito, T.; Hosaka, Y.; Ikeda, T.; Nakamura, K.;</span></p>
<p style="top:585.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Chung, U.; et al. Lack of a chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ect of cyclooxygenase 2 inhibition in a surgically induced</span></p>
<p style="top:597.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">model of osteoarthritis in mice.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Arthritis Rheum.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 64</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 198&#x2013;203. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:610.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">15.</span></p>
<p style="top:610.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ou, Y.; Tan, C.; An, H.; Jiang, D.; Quan, Z.; Tang, K.; Luo, X. Selective COX-2 inhibitor ameliorates</span></p>
<p style="top:623.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">osteoarthritis by repressing apoptosis of chondrocyte.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Med. Sci. Monit.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, BR247&#x2013;BR252. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:636.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">16.</span></p>
<p style="top:636.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ashkavand, Z.; Malekinejad, H.; Amniattalab, A.; Rezaei-Golmisheh, A.; Vishwanath, B.S. Silymarin</span></p>
<p style="top:649.5pt;left:97.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">potentiates the anti-in&#xfb02;ammatory e</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ects of Celecoxib on chemically induced osteoarthritis in rats.</span></p>
<p style="top:662.5pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Phytomedicine</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 19</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1200&#x2013;1205. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:675.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">17.</span></p>
<p style="top:675.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Moon, S.J.; Park, J.S.; Jeong, J.H.; Yang, E.J.; Park, M.K.; Kim, E.K.; Park, S.H.; Kim, H.Y.; Cho, M.L.; Min, J.K.</span></p>
<p style="top:688.3pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Augmented chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ect of coadministration of celecoxib and rebamipide in the monosodium</span></p>
<p style="top:701.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">iodoacetate rat model of osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Arch. Pharm. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 36</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 116&#x2013;124. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:714.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">18.</span></p>
<p style="top:714.1pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Panahifar, A.; Jaremko, J.L.; Tessier, A.G.; Lambert, R.G.; Maksymowych, W.P.; Fallone, B.G.; Doschak, M.R.</span></p>
<p style="top:727.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Development and reliability of a multi-modality scoring system for evaluation of disease progression in</span></p>
<p style="top:740.0pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">pre-clinical models of osteoarthritis: Celecoxib may possess disease-modifying properties.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Osteoarthritis Cartilage</span></i></p>
<p style="top:752.9pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1639&#x2013;1650. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">14 of 15</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">19.</span></p>
<p style="top:90.6pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Li, Z.; Meng, D.; Li, G.; Xu, J.; Tian, K.; Li, Y. Celecoxib Combined with Diacerein Effectively Alleviates</span></p>
<p style="top:103.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Inflammation</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 38</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1563&#x2013;1572.</span></p>
<p style="top:116.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:129.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">20.</span></p>
<p style="top:129.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Dai, M.W.; Chu, J.G.; Tian, F.M.; Song, H.P.; Wang, Y.; Zhang, Y.Z.; Zhang, L. Parathyroid hormone(1-34)</span></p>
<p style="top:142.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">exhibits more comprehensive e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ects than celecoxib in cartilage metabolism and maintaining subchondral</span></p>
<p style="top:155.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">bone micro-architecture in meniscectomized guinea pigs.</span></p>
<p style="top:155.2pt;left:343.5pt;line-height:9.1pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 1103&#x2013;1112.</span></p>
<p style="top:168.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:181.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">21.</span></p>
<p style="top:181.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Tu, M.; Yang, M.; Yu, N.; Zhen, G.; Wan, M.; Liu, W.; Ji, B.; Ma, H.; Guo, Q.; Tong, P.; et al. Inhibition of</span></p>
<p style="top:193.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">cyclooxygenase-2 activity in subchondral bone modi&#xfb01;es a subtype of osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Bone Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 7</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 29.</span></p>
<p style="top:206.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:219.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">22.</span></p>
<p style="top:219.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Jones, M.D.; Tran, C.W.; Li, G.; Maksymowych, W.P.; Zernicke, R.F.; Doschak, M.R.</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> In vivo</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> microfocal</span></p>
<p style="top:232.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and</span></p>
<p style="top:245.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">antiin&#xfb02;ammatory drugs as preventive treatments of osteoarthritis in the rat.</span></p>
<p style="top:245.5pt;left:426.0pt;line-height:9.1pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Arthritis Rheum.</span></i></p>
<p style="top:245.6pt;left:499.6pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:258.5pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">62</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2726&#x2013;2735. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:271.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">23.</span></p>
<p style="top:271.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Nagy, E.; Vajda, E.; Vari, C.; Sipka, S.; Farr, A.M.; Horvath, E. Meloxicam ameliorates the cartilage and</span></p>
<p style="top:284.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">subchondral bone deterioration in monoiodoacetate-induced rat osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> PeerJ</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 5</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, e3185. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:297.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">24.</span></p>
<p style="top:297.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wen, Z.H.; Lin, Y.Y.; Chang, Y.C.; Tang, C.C.; Hsieh, S.P.; Lee, H.P.; Sung, C.S.; Chen, W.F.; Lee, C.H.; Jean, J.H.</span></p>
<p style="top:310.1pt;left:97.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">The COX-2 inhibitor etoricoxib reduces experimental osteoarthritis and nociception in rats: The roles of</span></p>
<p style="top:323.1pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">TGF-beta1 and NGF expressions in chondrocytes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Eur. J. Pain.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 209&#x2013;222. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:336.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">25.</span></p>
<p style="top:335.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Liu, B.; Ji, C.; Shao, Y.; Liang, T.; He, J.; Jiang, H.; Chen, G.; Luo, Z. Etoricoxib decreases subchondral</span></p>
<p style="top:348.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">bone mass and attenuates biomechanical properties at the early stage of osteoarthritis in a mouse model.</span></p>
<p style="top:361.8pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biomed Pharmacother</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 127</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 110144. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:374.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">26.</span></p>
<p style="top:374.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Jiang, D.; Zou, J.; Huang, L.; Shi, Q.; Zhu, X.; Wang, G.; Yang, H. E</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">cacy of intra-articular injection of</span></p>
<p style="top:387.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">celecoxib in a rabbit model of osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 4106. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:400.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">27.</span></p>
<p style="top:400.6pt;left:98.0pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Dong,J.; Jiang,D.; Wang, Z.; Wu,G.; Miao,L.; Huang, L.Intra-articulardeliveryofliposomalcelecoxib-hyaluronate</span></p>
<p style="top:413.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">combination for the treatment of osteoarthritis in rabbit model.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Pharm.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 441</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 285&#x2013;290. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:426.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">28.</span></p>
<p style="top:426.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Janssen, M.; Timur, U.T.; Woike, N.; Welting, T.J.; Draaisma, G.; Gijbels, M.; van Rhijn, L.W.; Mihov, G.;</span></p>
<p style="top:439.4pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Thies, J.C.; Emans, P.J. Celecoxib-loaded PEA microspheres as an auto regulatory drug-delivery system after</span></p>
<p style="top:452.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">intra-articular injection.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Control Release.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 244</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 30&#x2013;40. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:465.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">29.</span></p>
<p style="top:465.0pt;left:98.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Tellegen, A.R.; Rudnik-Jansen, I.; Pouran, B.; De Visser, H.M.; Weinans, H.H.; Thomas, R.E.; Kik, M.J.L.;</span></p>
<p style="top:478.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Grinwis, G.C.M.; Thies, J.C.; Woike, N.; et al. Controlled release of celecoxib inhibits inflammation, bone cysts</span></p>
<p style="top:490.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and osteophyte formation in a preclinical model of osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Drug Deliv.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 25</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1438&#x2013;1447. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:503.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">30.</span></p>
<p style="top:503.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Jean, Y.H.; Wen, Z.H.; Chang, Y.C.; Hsieh, S.P.; Tang, C.C.; Wang, Y.H.; Wong, C.S. Intra-articular injection</span></p>
<p style="top:516.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">of the cyclooxygenase-2 inhibitor parecoxib attenuates osteoarthritis progression in anterior cruciate</span></p>
<p style="top:529.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ligament-transected knee in rats: Role of excitatory amino acids.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 638&#x2013;645.</span></p>
<p style="top:542.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:555.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">31.</span></p>
<p style="top:555.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wen, Z.H.; Tang, C.C.; Chang, Y.C.; Huang, S.Y.; Chen, C.H.; Wu, S.C.; Hsieh, S.P.; Hsieh, C.S.; Wang, K.Y.;</span></p>
<p style="top:568.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lin, S.Y.; et al. Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces</span></p>
<p style="top:581.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">experimental osteoarthritis and nociception in rats.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1976&#x2013;1986. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:594.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:607.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">32.</span></p>
<p style="top:607.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Liu, P.; Gu, L.; Ren, L.; Chen, J.; Li, T.; Wang, X.; Yang, J.; Chen, C.; Sun, L. Intra-articular injection of</span></p>
<p style="top:620.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">etoricoxib-loaded PLGA-PEG-PLGA triblock copolymeric nanoparticles attenuates osteoarthritis progression.</span></p>
<p style="top:633.0pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Am. J. Transl. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 11</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 6775&#x2013;6789. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:645.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">33.</span></p>
<p style="top:645.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Tindall, E.A.; Sharp, J.T.; Burr, A.; Katz, T.K.; Wallemark, C.B.; Verburg, K.; Lefkowith, J. A 12-month,</span></p>
<p style="top:658.8pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of</span></p>
<p style="top:671.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">the knee or hip in patients receiving celecoxib.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Clin Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2002</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2051&#x2013;2063. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:684.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">34.</span></p>
<p style="top:684.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Sawitzke, A.D.; Shi, H.; Finco, M.F.; Dunlop, D.D.; 3rd Bingham, C.O.; Harris, C.L.; Singer, N.G.; Bradley, J.D.;</span></p>
<p style="top:697.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Silver, D.; Jackson, C.G.; et al. The e</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ect of glucosamine and</span><span style="font-family:Rpxr,serif;font-size:9.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">or chondroitin sulfate on the progression of</span></p>
<p style="top:710.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">knee osteoarthritis: A report from the glucosamine</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">chondroitin arthritis intervention trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Arthritis Rheum.</span></i></p>
<p style="top:723.3pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2008</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 58</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3183&#x2013;3191. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Int. J. Mol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 6962</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">15 of 15</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">35.</span></p>
<p style="top:90.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">De Boer, T.N.; Huisman, A.M.; Polak, A.A.; Nieho</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, A.G.; Van Rinsum, A.C.; Saris, D.; Bijlsma, J.W.J.;</span></p>
<p style="top:103.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lafeber, F.J.P.G.; Mastbergen, S.C. The chondroprotective e</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">ect of selective COX-2 inhibition in osteoarthritis:</span></p>
<p style="top:116.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ex vivo evaluation of human cartilage tissue after</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> treatment.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 482&#x2013;488.</span></p>
<p style="top:129.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:142.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">36.</span></p>
<p style="top:142.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Raynauld, J.P.; Martel-Pelletier, J.; Beaulieu, A.; Bessette, L.; Morin, F.; Choquette, D.; Haraoui, B.; Abram, F.;</span></p>
<p style="top:155.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Pelletier, J.P. An open-label pilot study evaluating by magnetic resonance imaging the potential for a</span></p>
<p style="top:168.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">disease-modifying e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ect of celecoxib compared to a modelized historical control cohort in the treatment of</span></p>
<p style="top:181.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">knee osteoarthritis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Semin. Arthritis Rheum.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 40</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 185&#x2013;192. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:194.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">37.</span></p>
<p style="top:194.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Riendeau, D.; Percival, M.D.; Brideau, C.; Charleson, S.; Dub</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe9;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, D.; Ethier, D.; Falgueyret, J.P.; Friesen, R.W.;</span></p>
<p style="top:206.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Gordon, R.; Greig, G.; et al. Etoricoxib (MK-0663): Preclinical Pro&#xfb01;le and Comparison with other agents that</span></p>
<p style="top:219.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">selectively inhibit Cyclooxygenase-2.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Pharmacol. Exp. Ther.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2001</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 296</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 558&#x2013;566.</span></p>
<p style="top:232.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">38.</span></p>
<p style="top:232.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Loeser, R.F.; Goldring, S.R.; Scanzello, C.R.; Goldring, M.B. Osteoarthritis: A disease of the joint as an organ.</span></p>
<p style="top:245.6pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Arthritis Rheum.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 64</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1697&#x2013;1707. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:258.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">39.</span></p>
<p style="top:258.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Clockaerts, S.; Bastiaansen-Jenniskens, Y.M.; Runhaar, J.; Van Osch, G.J.; Van O</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">el, J.F.; Verhaar, J.A.;</span></p>
<p style="top:271.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">de Clerck, L.S.; Somville, J. The infrapatellar fat pad should be considered as an active osteoarthritic joint</span></p>
<p style="top:284.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tissue: A narrative review.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 876&#x2013;882. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:297.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">40.</span></p>
<p style="top:297.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Weinberg, J.B.; Fermor, B.; Guilak, F. Nitric oxide synthase and cyclooxygenase interactions in cartilage and</span></p>
<p style="top:310.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">meniscus: Relationships to joint physiology, arthritis, and tissue repair.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Subcell Biochem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2007</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 42</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 31&#x2013;62.</span></p>
<p style="top:323.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">41.</span></p>
<p style="top:323.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">De Lange-Brokaar, B.J.; Ioan-Facsinay, A.; Van Osch, G.J.; Zuurmond, A.M.; Schoones, J.; Toes, R.E.;</span></p>
<p style="top:336.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Huizinga, T.W.J.; Kloppenburg, M. Synovial in&#xfb02;ammation, immune cells and their cytokines in osteoarthritis:</span></p>
<p style="top:348.9pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">A review.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1484&#x2013;1499. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:361.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">42.</span></p>
<p style="top:361.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Bastiaansen-Jenniskens, Y.M.; Wei, W.; Feijt, C.; Waarsing, J.H.; Verhaar, J.A.; Zuurmond, A.M.;</span></p>
<p style="top:374.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hanemaaijer, R.; Stoop, R.; van Osch, G.J.V.M. Stimulation of &#xfb01;brotic processes by the infrapatellar fat</span></p>
<p style="top:387.6pt;left:97.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">pad in cultured synoviocytes from patients with osteoarthritis: A possible role for prostaglandin f2alpha.</span></p>
<p style="top:400.6pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Arthritis Rheum.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 65</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2070&#x2013;2080. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:413.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">43.</span></p>
<p style="top:413.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Welting, T.J.; Caron, M.M.; Emans, P.J.; Janssen, M.P.; Sanen, K.; Coolsen, M.M.; Voss, L.; Surtel, D.A.;</span></p>
<p style="top:426.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Cremers, A.; Voncken, J.; et al.</span></p>
<p style="top:426.3pt;left:242.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic</span></p>
<p style="top:439.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">di</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">erentiation during endochondral ossi&#xfb01;cation.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Eur. Cell Mater.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 420&#x2013;437. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:452.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">44.</span></p>
<p style="top:452.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Felson, D.T.; Niu, J.; Neogi, T.; Goggins, J.; Nevitt, M.C.; Roemer, F.; Torner, J.; Lewis, C.E.; Guermazi, A.</span></p>
<p style="top:465.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Synovitis and the risk of knee osteoarthritis: The MOST Study.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 458&#x2013;464.</span></p>
<p style="top:478.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:490.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">45.</span></p>
<p style="top:491.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Karin, M.; Clevers, H. Reparative in&#xfb02;ammation takes charge of tissue regeneration.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nature</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 529</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 307&#x2013;315.</span></p>
<p style="top:503.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:516.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">46.</span></p>
<p style="top:516.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Glyn-Jones, S.; Palmer, A.J.; Agricola, R.; Price, A.J.; Vincent, T.L.; Weinans, H.; Carr, A.J. Osteoarthritis.</span></p>
<p style="top:529.7pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lancet</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 386</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 376&#x2013;387. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:542.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">47.</span></p>
<p style="top:542.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Karsdal, M.A.; Christiansen, C.; Ladel, C.; Henriksen, K.; Kraus, V.B.; Bay-Jensen, A.C. Osteoarthritis&#x2013;a case</span></p>
<p style="top:555.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">for personalized health care?</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Osteoarthritis Cartilage</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 7&#x2013;16. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:568.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">48.</span></p>
<p style="top:568.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Waarsing, J.H.; Bierma-Zeinstra, S.M.; Weinans, H. Distinct subtypes of knee osteoarthritis: Data from the</span></p>
<p style="top:581.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Osteoarthritis Initiative.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Rheumatology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 54</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1650&#x2013;1658. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:594.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">49.</span></p>
<p style="top:594.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Oei, E.H.G.; Wick, M.C.; Muller-Lutz, A.; Schleich, C.; Miese, F.R. Cartilage Imaging: Techniques and</span></p>
<p style="top:607.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Developments.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Semin. Musculoskelet. Radiol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 245&#x2013;260. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<img style="position:absolute;transform:matrix(.221696,0,-0,.221696,-91.16266,772.1337)" src="data:image/png;base64,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">
<p style="top:629.0pt;left:167.8pt;line-height:9.0pt"><span style="font-family:Rpcxr,serif;font-size:9.0pt">&#xa9;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access</span></p>
<p style="top:641.9pt;left:169.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">article distributed under the terms and conditions of the Creative Commons Attribution</span></p>
<p style="top:654.9pt;left:169.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(CC BY) license (http:</span><span style="font-family:Rpxr,serif;font-size:9.0pt">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">creativecommons.org</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">licenses</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">by</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.0</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">).</span></p>

</div>
